The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Transplantation Proceedings

• Publication date

  1994-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 7940928
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved Dose Linearity of Cyclosporine Pharmacokinetics from a Microemulsion Formulation

  1994cited by this paper
• Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation

  1993cited by this paper
• THE ABILITY OF PRETRANSPLANT TEST‐DOSE PHARMACOKINETIC PROFILES TO REDUCE EARLY ADVERSE EVENTS AFTER RENAL TRANSPLANTATION1, 2

  1992cited by this paper
• Specific monoclonal radioimmunoassay and fluorescence polarization immunoassay for trough concentration and area-under-the-curve monitoring of cyclosporine in renal transplantation.

  1992cited by this paper
• Improvement of peroral absorption of cyclosporine A by microemulsions.

  1990cited by this paper
• Absorption kinetics of cyclosporine in healthy volunteers.

  1989cited by this paper
• The effect of food on cyclosporine absorption.

  1985cited by this paper

• A novel biomarker of chronic allograft dysfunction in renal transplant recipients (serum calreticulin and CD47)

  2020cites this paper
• Fifty years in the vineyard of transplantation: looking back.

  2011cites this paper
• Forty years of publication of transplantation proceedings-the third decade: the expansion of the enterprise.

  2009cites this paper
• New directions in cardiac transplantation.

  2006cites this paper
• Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.

  2006cites this paper
• New Concepts

  2005cites this paper
• Chapter 36 – Diagnosis and Therapy of Graft Dysfunction

  2005cites this paper
• [Cyclosporine dose monitorization in renal transplantation C2 vs C0].

  2005cites this paper
• Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy.

  2005cites this paper
• Dose Adjustment Strategy for Oral Microemulsion Formulation of Cyclosporine: Population Pharmacokinetics-Based Analysis in Kidney Transplant Patients

  2004cites this paper
• Experience with cyclosporine.

  2004cites this paper
• History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion.

  2004cites this paper
• Improved absorption of cyclosporin A from a new microemulsion formulation: implications for dosage and monitoring

  2004cites this paper
• Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery

  2002cites this paper
• Two-Hour Cyclosporine Concentration Determination: An Appropriate Tool to Monitor Neoral Therapy?

  2002cites this paper
• Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2)1

  2002cites this paper
• Treatment pathways and economic analysis of treatment for severe psoriasis

  2002cites this paper
• Three-hour postdose cyclosporine level monitoring: less rejection and more nephrotoxicity?

  2001cites this paper
• Recent advances in therapeutic monitoring of cyclosporine: Absorption profiling

  2001cites this paper
• Pharmacokinetics of cyclosporin in children with stable renal transplants

  2000cites this paper
• Neoral dose monitoring with cyclosporine 2-hour postdose levels in heart transplant patients receiving anti-thymocyte globulin induction.

  2000cites this paper
• TRANSPLANT AT ION / O RIGINAL AR T ICLE

  2000cites this paper
• Optimization of cyclosporine therapy with abbreviated area under the curve method in renal transplant.

  2000cites this paper
• COMPARATIVE LONG-TERM EVALUATION OF TACROLIMUS AND CYCLOSPORINE IN PEDIATRIC LIVER TRANSPLANTATION

  2000cites this paper
• Influence of drug formulation on utilization and outcomes: Neoral and monitoring by sparse sample area under the curve.

  1999cites this paper
• US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis.

  1999cites this paper
• Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral.

  1999cites this paper
• Immunosuppressive therapy.

  1999cites this paper
• A Prospective Study on Conversion from Sandimmune to Neoral in Stable Adult Liver Transplant Recipients

  1999cites this paper
• IMMUNOSUPPRESSIVE THERAPY: New Concepts

  1999cites this paper
• Improved cyclosporine bioavailability in black pediatric liver transplant recipients after administration of the microemulsion formulation.

  1999cites this paper
• Ciclosporin microemulsion preconcentrate treatment of patients with Behçet's disease.

  1999cites this paper
• Cyclosporine A in rheumatoid arthritis: randomized, placebo controlled dose finding study.

  1999cites this paper
• Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation.

  1999cites this paper
• Sandimmune® to neoral® conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients

  1999cites this paper
• Pharmacokinetic study of twice vs thrice daily dosing of Sandimmun Neoral in pediatric renal transplant patients.

  1998cites this paper
• Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus.

  1998cites this paper
• Immunosuppressive approaches to the prevention of graft vascular disease.

  1998cites this paper
• Benefits of pre‐emptive dose reduction for Sandimmune to Neoral conversion in stable renal transplant recipients

  1998cites this paper
• THERAPEUTIC DRUG MONITORING OF CYCLOSPORINE AND TACROLIMUS

  1998cites this paper
• Two‐hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy 1

  1998cites this paper
• Neoral reduces the incidence of acute rejection after renal transplantation.

  1998cites this paper
• Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.

  1998cites this paper
• Neoral increases bioavailability versus oral Sandimmune after porcine small bowel transplantation.

  1998cites this paper
• Reduced acute rejection and side effects with neoral in liver transplantation.

  1998cites this paper
• Conversion to cyclosporine microemulsion (Neoral) in stable renal transplant patients: results from a single center.

  1998cites this paper
• Sandimmun-to-Neoral conversion in stable pediatric kidney transplant recipients.

  1998cites this paper
• Abbreviating area under the curves further: a practical approach to monitoring extended pharmacokinetics with Neoral.

  1998cites this paper
• Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients.

  1998cites this paper
• Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation.

  1998cites this paper
• SAFETY AND TOLERABILITY OF CYCLOSPORINE AND CYCLOSPORINE MICROEMULSION DURING 18 MONTHS OF FOLLOW-UP IN STABLE RENAL TRANSPLANT RECIPIENTS

  1998cites this paper
• Circadian Variations in the Pharmacokinetics of a New Microemulsion Formulation of Cyclosporine in Cardiac Transplant Recipients

  1998cites this paper
• Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients.

  1998cites this paper
• Immunosuppression and Treatment of Rejection

  1998cites this paper
• [Conversion from +Sandimmune to Neoral in kidney transplant recipients treated with cyclosporine and ketoconazole].

  1997cites this paper
• Renal function following conversion from Sandimmune to Neoral in stable renal transplant recipients.

  1997cites this paper
• Renal Function following Conversion from Sandimmune to Neoral in Stable Renal Transplant Recipients

  1997cites this paper
• A pharmacokinetic comparison of the corn oil versus microemulsion gelcap formulation of cyclosporin used de novo after renal transplantation

  1997cites this paper
• Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.

  1997cites this paper
• Equivalence of cyclosporine blood level assays in patients receiving cyclosporine microemulsion or cyclosporine

  1997cites this paper
• Effect of assay methodology on pharmacokinetic differences between cyclosporine Neoral and Sandimmune formulations.

  1997cites this paper
• Comparison of Neoral and Sandimmune cyclosporine for induction of immunosuppression after heart transplantation.

  1997cites this paper
• Cyclosporine Neoral in renal transplant recipients: impact on hepatic dysfunction.

  1997cites this paper
• A Pharmacokinetic Study of Cyclosporin (Sandimmune®)

  1997cites this paper
• Pharmacokinetic cyclosporine A profiles under long-term Neoral treatment in renal transplant recipients: does fat intake still matter?

  1997cites this paper
• Cholestasis-Related Cyclosporin Malabsorption Overcome by Administration of Sandimmun Neoral®

  1996cites this paper
• Pharmacokinetic analysis of Neoral conversion in pediatric and adult renal transplant recipients with poor absorption of Sandimmune.

  1996cites this paper
• Conversion from Sandimmune to Neoral in stable renal and pancreas transplant recipients enhances cyclosporine absorption.

  1996cites this paper
• Improved absorption of cyclosporine for microemulsion in a pediatric liver transplant recipient with cystic fibrosis.

  1996cites this paper
• Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral

  1996cites this paper
• Pharmacology of immunosuppressive medications used in renal diseases and transplantation.

  1996cites this paper
• Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation.

  1996cites this paper
• Pharmacokinetic profile of cyclosporine A after conversion to Sandimmun Optoral: influence on ambulatory blood pressure in renal transplant patients.

  1996cites this paper
• The Use of Therapeutic Drug Monitoring to Optimise Immunosuppressive Therapy

  1996cites this paper
• Comparison of the absorption pharmacokinetics of Sandimmune and Neoral following porcine small bowel transplantation.

  1996cites this paper
• Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period.

  1996cites this paper
• The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. The Neoral Study Group.

  1996cites this paper
• Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients.

  1996cites this paper
• An open randomized parallel group study to compare Sandimmune Neoral with Sandimmune soft gelatin capsule in stable renal transplant patients.

  1996cites this paper
• Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in immediate posttransplant period.

  1996cites this paper
• Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group.

  1996cites this paper
• The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group.

  1996cites this paper
• Follow-up after conversion to Neoral in stable heart transplant recipients.

  1996cites this paper
• Clinically Significant Drug Interactions with Cyclosporin An Update

  1996cites this paper
• A New Microemulsion Formulation of Cyclosporin

  1996cites this paper
• Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients.

  1996cites this paper
• Maintenance Immunosuppressive Drug Therapy and Potential Major Complications

  1996cites this paper
• The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients

  1996cites this paper
• In vitro study of cyclosporin absorption: Vehicles and intestinal immaturity

  1996cites this paper
• Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group.

  1995cites this paper
• Improved absorption of cyclosporin A from a new microemulsion formulation: implications for dosage and monitoring

  1995cites this paper
• Optimizing the use of cyclosporine in renal transplantation.

  1995cites this paper
• Eosinophils in urine revisited

  1995cites this paper
• Neoral--a new microemulsion formula of cyclosporine A: interpatient pharmacokinetic variability in renal transplant recipients.

  1995cites this paper